KR101072133B1 - Skin whitening composition having synergic whitening effect - Google Patents
Skin whitening composition having synergic whitening effect Download PDFInfo
- Publication number
- KR101072133B1 KR101072133B1 KR1020040002910A KR20040002910A KR101072133B1 KR 101072133 B1 KR101072133 B1 KR 101072133B1 KR 1020040002910 A KR1020040002910 A KR 1020040002910A KR 20040002910 A KR20040002910 A KR 20040002910A KR 101072133 B1 KR101072133 B1 KR 101072133B1
- Authority
- KR
- South Korea
- Prior art keywords
- whitening
- skin
- extract
- licorice
- red ginseng
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000002087 whitening effect Effects 0.000 title claims abstract description 43
- 230000002195 synergetic effect Effects 0.000 title abstract 2
- 239000000284 extract Substances 0.000 claims abstract description 49
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 26
- 235000018185 Betula X alpestris Nutrition 0.000 claims abstract description 23
- 235000018212 Betula X uliginosa Nutrition 0.000 claims abstract description 23
- 108090000526 Papain Proteins 0.000 claims abstract description 23
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 21
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 21
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 21
- 229940010454 licorice Drugs 0.000 claims abstract description 21
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 241000202807 Glycyrrhiza Species 0.000 claims description 20
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 28
- 239000004365 Protease Substances 0.000 abstract description 8
- 229940069445 licorice extract Drugs 0.000 abstract description 8
- 235000019834 papain Nutrition 0.000 abstract description 8
- 229940055729 papain Drugs 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 238000012261 overproduction Methods 0.000 abstract description 3
- 241000208340 Araliaceae Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 29
- 238000009472 formulation Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 12
- 230000008099 melanin synthesis Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000010487 meadowfoam seed oil Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108010001078 naringinase Proteins 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000008417 skin turnover Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
- F16B35/00—Screw-bolts; Stay-bolts; Screw-threaded studs; Screws; Set screws
- F16B35/04—Screw-bolts; Stay-bolts; Screw-threaded studs; Screws; Set screws with specially-shaped head or shaft in order to fix the bolt on or in an object
- F16B35/06—Specially-shaped heads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
- F16B23/00—Specially shaped nuts or heads of bolts or screws for rotations by a tool
- F16B23/0007—Specially shaped nuts or heads of bolts or screws for rotations by a tool characterised by the shape of the recess or the protrusion engaging the tool
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
- F16B37/00—Nuts or like thread-engaging members
- F16B37/14—Cap nuts; Nut caps or bolt caps
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mechanical Engineering (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 멜라닌 과다생성 억제 및 피부에 생성된 멜라닌의 배출을 촉진시켜 미백효과를 증진시켜 주는 화장료 조성물에 관한 것으로, 더욱 상세하게는 감초추출물, 홍삼추출물, 자작나무추출물, 파파인 효소를 함유하여 피부에 미백효과를 증진시켜 주는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for inhibiting melanin overproduction and promoting the release of melanin produced in the skin to enhance the whitening effect, more specifically licorice extract, red ginseng extract, birch extract, papain enzyme It relates to a cosmetic composition that enhances the whitening effect.
감초, 미백, 인삼, 자작나무, 파파인, 미백상승효과Licorice, whitening, ginseng, birch, papain, whitening synergistic effect
Description
본 발명은 멜라닌 과다생성 억제 및 피부에 생성된 멜라닌의 배출을 촉진시켜 미백효과를 증진시켜 주는 화장료 조성물에 관한 것으로, 더욱 상세하게는, 홍삼추출물, 자작나무추출물 및 파파인 효소를 함유하여, 피부 미백성분인 감초의 미백효과를 상승시켜주는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for promoting melanin overproduction and promoting the release of melanin produced in the skin to enhance the whitening effect, more specifically, red ginseng extract, birch extract and papain enzyme, skin whitening It relates to a cosmetic composition for increasing the whitening effect of licorice which is a component.
자외선에 피부가 노출되게 되면 사람의 피부색을 결정하는 멜라닌(melanin)이 합성되고 방출되어 기미나 주근깨, 점등과 같은 과색소침착증을 유발하여 미용상 좋지 않은 결과를 가져오게 된다. When the skin is exposed to ultraviolet rays, melanin (melanin), which determines the color of a person's skin, is synthesized and released, causing hyperpigmentation such as blemishes, freckles, and lighting, resulting in cosmetic consequences.
멜라닌이 합성되는 과정은, 세포내의 티로신(tyrosine)을 기질로 하여 티로시나아제(tyrosinase)효소가 작용하여 도파퀴논(dopaquinone)을 형성하고, 도파퀴논으로부터 멜라닌이 생성되는 메카니즘을 갖는다. 따라서, 피부가 검게되는 것을 막기 위하여 멜라닌 생성과정 중 어느 특정 과정을 저해하여 멜라닌 합성자체를 감소시키는 방법이 일반적으로 연구되고 있다. 이렇게 개발된 미백제로는 코지산, 알부틴, 감초, 비타민 A, 비타민 C등이 있다. The process of synthesizing melanin has a mechanism in which tyrosinase acts as a substrate to form dopaquinone and forms melanin from dopaquinone. Therefore, in order to prevent the skin from becoming black, a method of reducing melanin synthesis by inhibiting any specific process of melanin production is generally studied. Whitening agents thus developed include kojic acid, arbutin, licorice, vitamin A, and vitamin C.
그렇지만, 멜라닌은 피부색을 결정하는 역할이외에도 핵주변에 모자와 같은 구조를 형성하여 자외선으로부터 유전자를 보호하고, 자유 라디칼(free radical)을 제거하여 세포 내 단백질을 보호하는 등 중요한 역할을 담당하고 있다. 그 결과, 멜라닌 생성 자체를 과도하게 억제하는 것은 피부에서 필요한 최소한의 역할을 수행하지 못할 가능성이 있다는 문제점이 있다.However, in addition to determining the skin color, melanin plays an important role such as forming a hat-like structure around the nucleus to protect genes from ultraviolet rays and to remove free radicals to protect intracellular proteins. As a result, there is a problem that excessively inhibiting melanin production itself may not perform the minimum required role in the skin.
따라서, 과도하게 생성된 멜라닌만을 선택적으로 빨리 제거함으로써 피부의 톤을 밝게 하는 쪽으로의 접근방법이 필요할 것으로 사료된다.Therefore, it is considered that an approach toward brightening skin tone by selectively removing only excessively produced melanin is needed.
이에, 본 발명자들은 상기한 문제점을 해결하기 위하여 피부 구조와 연계하여 3가지 측면에서 피부 미백을 증진하기 위하여 연구하였다. Thus, the present inventors studied to improve skin whitening in three aspects in connection with the skin structure to solve the above problems.
그 결과, 첫째 피부의 각질층 중에서도 제일 바깥쪽에 있는 세포의 탈리를 증진시키기 위하여 파파인 효소를 사용하고, 둘째 세포 성장을 촉진시키기 위하여 홍삼추출물을 사용하며, 셋째 자작나무 추출물을 사용하여 거친 피부를 유연하게 만들어 줌으로써 전체적으로는 피부의 턴오버 메카니즘을 극대화하여, 결과적으로는 피부에 미백효과를 높일 수 있음을 밝혀 본 발명을 완성하였다.As a result, first, papain enzyme is used to enhance detachment of the outermost cells of the stratum corneum of the skin, red ginseng extract is used to promote cell growth, and third, the birch extract is used to soften rough skin. The present invention was completed by maximizing the turnover mechanism of the skin as a whole, thereby increasing the whitening effect on the skin.
따라서, 본 발명의 목적은 피부 미백 성분의 미백효능을 극대화시킬 수 있는 방법을 제공하는 것이다. 이에, 본 발명에서는 피부 미백 성분의 미백효능을 극대화시켜주는 조성물로서, 홍삼추출물, 자작나무추출물 및 파파인 효소를 함유하는 화장료 조성물을 제공한다.Accordingly, it is an object of the present invention to provide a method capable of maximizing the whitening efficacy of skin whitening ingredients. Thus, the present invention provides a cosmetic composition containing red ginseng extract, birch extract and papain enzyme as a composition for maximizing the whitening effect of the skin whitening component.
또한 본 발명은 홍삼추출물, 자작나무추출물 및 파파인 효소를 함유하고, 미 백성분으로서 감초를 함유하는 미백용 화장료 조성물을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide a cosmetic composition for whitening containing red ginseng extract, birch extract, and papain enzyme, and containing licorice as the untreated people.
본 발명은 감초 추출물, 홍삼추출물, 자작나무추출물 및 파파인 효소를 함유하는 미백용 화장료 조성물을 제공한다. The present invention provides a cosmetic composition for whitening containing licorice extract, red ginseng extract, birch extract and papain enzyme.
본 발명에 의한 상기 조성물은 멜라닌 과다생성 억제 및 피부에 생성된 멜라닌의 배출을 촉진시켜주어 결과적으로는 미백효과를 증진시켜 주는 화장료 조성물에 관한 것으로, 세포 박리 증진, 세포 생성 촉진, 피부유연화를 통한 피부 전체의 턴오버의 주기를 빠르게 할 수 있다.The composition according to the present invention relates to a cosmetic composition that inhibits melanin overproduction and promotes the release of melanin produced in the skin and consequently enhances the whitening effect, and promotes cell detachment, promotes cell production, and skin softening. You can speed up the turnover of your entire skin.
상기 감초 추출물, 홍삼추출물, 자작나무추출물 및 파파인 효소는 각각을 단독으로 사용할 때보다 동시에 사용할 때 그 미백효과가 예상치 못할 정도로 상승되는 것을 본 발명자들이 처음으로 발견하였다. 즉, 상기 성분들은 서로 혼합하여 사용함으로써 미백효과를 극대화할 수 있는 것이다. 이에 본 발명자들은 상기 감초 추출물, 홍삼추출물, 자작나무추출물 및 파파인 효소를 함유하는 미백용 조성물을 "화이트 에너지 콤플렉스"라고 명명하였다.The inventors have found for the first time that the licorice extract, red ginseng extract, birch extract and papain enzyme are unexpectedly elevated in their whitening effect when used simultaneously with each other. That is, the components can be mixed with each other to maximize the whitening effect. Thus, the inventors named the whitening composition containing the licorice extract, red ginseng extract, birch extract and papain enzyme as "white energy complex".
먼저 본 발명에 상기 감초는 멜라닌 생성 억제용 미백 활성의 주성분으로 작용한다. 상기 감초의 함량은 조성물 총 중량에 대하여 0.001∼2.0중량%가 적절하다. 0.001중량% 미만의 농도에서는 미백효과가 미미하며, 2.0중량%를 초과하는 농도에서는 피부 자극을 유발할 수 있기 때문이다.First, the licorice in the present invention acts as a main component of the whitening activity for inhibiting melanin production. The licorice content is appropriately 0.001 to 2.0% by weight based on the total weight of the composition. This is because the whitening effect is insignificant at a concentration of less than 0.001% by weight, and skin irritation may be caused at a concentration of more than 2.0% by weight.
파파인 효소는 주로 세포의 탈리를 증진시키는 기능을 하는데, 조성물 총 중 량에 대하여 0.01∼0.1중량%가 적절하다. 0.01중량% 미만의 농도에서는 그 효과가 미미하며, 0.1중량%를 초과하는 농도에서는 피부자극을 유발할 수 있기 때문이다.Papain enzyme mainly functions to promote cell detachment, and 0.01 to 0.1% by weight is appropriate for the total weight of the composition. This is because the effect is insignificant at a concentration of less than 0.01% by weight, and skin irritation may be caused at a concentration of more than 0.1% by weight.
홍삼 추출물은 세포 성장을 촉진시키기는 역할을 주로 담당한다. 바람직하게는 6년근 홍삼이 가격 및 효능 면에서 적당하다. 사용량은 조성물 총 중량에 대하여 0.01∼5.0 중량%가 적절하다. 0.01중량% 미만의 농도에서는 효과를 기대하기 어려우며, 5.0 중량%를 초과하는 농도에서는 비용의 부담이 발생한다.Red ginseng extract mainly plays a role in promoting cell growth. Preferably 6 year old red ginseng is suitable in terms of price and efficacy. The amount of use is suitably 0.01 to 5.0% by weight based on the total weight of the composition. It is difficult to expect an effect at the concentration below 0.01 weight%, and the cost burden arises at the concentration exceeding 5.0 weight%.
자작나무 추출물은 피부의 유연화에 기여한다. 사용량은 조성물 총 중량에 대하여 0.01∼5.0 중량%가 적절하다. 0.01 중량% 미만의 농도에서는 효과를 기대하기 어려우며, 5.0 중량%를 초과하는 농도에서는 자극을 유발할 수 있다.Birch extract contributes to the softening of the skin. The amount of use is suitably 0.01 to 5.0% by weight based on the total weight of the composition. At concentrations below 0.01% by weight it is difficult to expect an effect and at concentrations above 5.0% by weight it may cause irritation.
상기 성분들의 효능은 상기 설명한 각각의 효능 외에 서로 혼합되어 사용됨으로써 서로 상승작용을 일으키는데 더 큰 효용성이 있다.
The potency of the ingredients is more effective in synergizing each other by being used in combination with each other in addition to the respective potency described above.
이하 본 발명을 보다 구체적으로 설명한다.Hereinafter, the present invention will be described in more detail.
지금까지 개발된 미백제는 멜라닌 생합성에 없어서는 안되는 기본적이면서도 가장 중요한 역할을 하는 효소인 티로시나아제(tyrosinase)의 활성을 저해하여 멜라닌 양을 줄이는 것이 대부분이었다. 이렇게 개발된 미백제들은 피부 자극을 유발하는 부작용에 의해 사용량이 제한되어 만족할 만한 미백효과를 나타낼 수 만큼 충분한 양을 사용하기 어려운 실정이다. 이에 미백효과를 내는 주된 미백성분은 그대로 사용하면서 미백효과를 높이기 위하여 피부 턴오버의 활성을 높여주는 시스 템을 사용함으로써 종래의 미백제보다 더 우수한 미백효과를 나타낼 수 있도록 한 것이 본 발명의 조성물이다.Until now, the whitening agent developed so far was to reduce the amount of melanin by inhibiting the activity of tyrosinase, a basic and most important enzyme that is indispensable for melanin biosynthesis. The whitening agents thus developed are limited in use due to side effects causing skin irritation, and thus, it is difficult to use a sufficient amount to produce a satisfactory whitening effect. The main whitening component that produces a whitening effect is to use the system to increase the skin turnover activity in order to increase the whitening effect as it is to show a better whitening effect than the conventional whitening agent.
피부는 얕은 층인 표피(epidermis)와 표피 밑의 보다 깊은 층인 진피(dermis)의 두 부분으로 구성되어 있으며, 진피의 밑에는 피부밑조직 (subcutaneous tissue)이라고 불리우는 별도의 결합조직층(피하조직)이 있다. 표피는 상피조직(epithelial tissue)으로 구성되어 있는 피부의 가장 바깥쪽 층으로서 모두 다섯개의 층으로 구성되어 있다. 구체적으로 바닥쪽에서부터 기저층 (basal layer), 가시층(spinous layer), 과립층(granular layer), 투명층(clear layer) 및 각질층(horny layer)으로 되어 있는데, 바닥쪽에서 계속 새 세포를 만들어내어 세포를 위로 밀어올리면서 각질화된 죽은 세포는 차츰 떨어져 나가게 됩니다. 이와같이 피부의 표피 바닥에서 새로운 세포가 만들어져서 오래된 세포를 피부 밖으로 밀어내서 체외로 떨어져 나가게 하는 주기를 턴-오버 주기라고 하는데, 본 발명에서는 이러한 턴-오버 주기를 촉진함으로써, 피부 표피에 생성되었던 멜라닌이 체외로 빨리 배출 될 수 있도록 하는 것이다.
The skin consists of two parts: the shallow epidermis (epidermis) and the deeper layer below the dermis (dermis), and under the dermis there is a separate layer of connective tissue called the subcutaneous tissue (subcutaneous tissue). . The epidermis is the outermost layer of skin, composed of epithelial tissue, consisting of five layers. Specifically, from the bottom side, it is composed of basal layer, spinous layer, granular layer, clear layer and horny layer. As you push up, dead cells that are exfoliated gradually fall off. As such, a cycle in which new cells are made at the skin's epidermal bottom to push old cells out of the skin and fall out of the body is called a turn-over cycle. This will allow them to be discharged out of the body quickly.
이하, 실시예 및 비교예를 들어 본 발명을 보다 상세히 설명한다. 그러나, 본 발명이 이들 실시예로만 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples. However, the present invention is not limited only to these examples.
<실시예 1 및 2> 미백 조성물의 제조 (화이트 에너지 콤플렉스 1 및 2)Examples 1 and 2 Preparation of Whitening Compositions (White Energy Complexes 1 and 2)
감초는 Maruzen Pharmaceuticals Co.Ltd(일본)의 글라브리딘이 35% 이상 함 유된 것으로 상품명으로는 Polyol soluble licorice ext P-T(40)을 사용하였다.Licorice contains 35% or more of glabridine from Maruzen Pharmaceuticals Co. Ltd. (Japan). The product name is Polyol soluble licorice ext P-T (40).
홍삼 추출물은 고제사의 6년근 홍삼추출액을 효소분해방법을 통하여 얻은 것을 사용하였다.
The red ginseng extract was obtained from Kojesa's six-year-old red ginseng extract obtained through enzymatic digestion.
* 효소분해방법* Enzyme digestion method
홍삼추출액 10g을 100㎖의 시트레이트 완충용액(pH 5.5)에 용해시키고, 여기에 페니실리움 속에서 분리한 나린지나제 효소 1g을 첨가하여 40℃ 수욕상에서 48시간 동안 교반시키면서 반응시켰다. 박층 크로마토그래피에 의해 주기적으로 확인하여, 기질이 완전히 소실되면 열수중에서 10분간 가열하여 반응을 종료시킨 다음, 반응액은 동량의 에테르로 3회 추출, 농축하였다. 얻은 생성물을 실리카겔 칼럼 크로마토그래피(크로로포름-메탄올=9:1)로 분리하여 홍삼추출물(수율 10.5%)을 얻었다.10 g of red ginseng extract was dissolved in 100 ml of citrate buffer (pH 5.5), and 1 g of naringinase enzyme isolated in penicillium was added thereto and reacted with stirring for 40 hours in a 40 ° C water bath. After periodic confirmation by thin layer chromatography, when the substrate was completely lost, the reaction was terminated by heating in hot water for 10 minutes, and then the reaction solution was extracted and concentrated three times with the same amount of ether. The obtained product was separated by silica gel column chromatography (chromoform-methanol = 9: 1) to obtain a red ginseng extract (yield 10.5%).
자작나무 추출물은 Arch Personal Care Products(미국)사의 제품(상품명: whitebirch extract)을 구입하여 사용하였다.Birch extract was used by purchasing a product (trade name: whitebirch extract) of Arch Personal Care Products (USA).
파파인 효소는 CPC Wolfgang Muhlbauer GmbH(독일)에서 제조한 Refined papain powder 상품명의 제품을 구입하여 사용하였다.
Papain enzyme was purchased from a product of the Refined papain powder brand manufactured by CPC Wolfgang Muhlbauer GmbH (Germany).
상기 추출들을 감초 추출물, 홍삼추출물, 자작나무추출물 및 파파인 효소를 5:5:10:0.3 의 비율로 혼합하여 본 발명의 미백용 조성물 (화이트 에너지 콤플렉스)1을 203g 제조하였다. (실시예 1) The extracts were mixed with licorice extract, red ginseng extract, birch extract and papain enzyme in a ratio of 5: 5: 10: 0.3 to prepare 203 g of a whitening composition (white energy complex) 1 of the present invention. (Example 1)
아울러, 상기 감초 추출물, 홍삼추출물, 자작나무추출물 및 파파인 효소를 5:10:20:0.6 의 비율로 혼합하여 화이트 에너지 콤플렉스 2를 356g제조하였다. (실시예 2)
In addition, the licorice extract, red ginseng extract, birch extract and papain enzyme were mixed at a ratio of 5: 10: 20: 0.6 to prepare 356 g of White Energy Complex 2. (Example 2)
<시험예 1> 멜라닌 생성억제 효과 측정<Test Example 1> melanin production inhibitory effect measurement
인간 멜라노마 세포인 HM3KO 세포(Y. Funasaka, Department of dermatology, Kobe university school of medicine, 5-1 Kusunoki-cho 7-chrome, Chuo-ku, Kobe 650, Japan)를 우태아혈청이 10% 들어간 Minimum Essential Medium (MEM)에 넣어 37℃, 5% CO2 조건하에서 배양하였다. 이렇게 배양한 세포를 세포수가 각 웰(well) 당 3×105 가 되도록 75 웰 플라스크에 분주하고, 하룻밤 동안 세포가 기벽에 붙기를 기다렸다. 세포가 잘 붙은 것을 확인한 후, 배지를 각각의 시험물질이 10ppm 들어 있는 새배지로 갈아주었다. HM3KO cells (Y. Funasaka, Department of dermatology, Kobe university school of medicine, 5-1 Kusunoki-cho 7-chrome, Chuo-ku, Kobe 650, Japan), human melanoma cells, contain 10% fetal bovine serum Incubated in Essential Medium (MEM) at 37 ℃, 5% CO 2 conditions. The cultured cells were dispensed into 75-well flasks so that the number of cells was 3 × 10 5 per well, and the cells were allowed to stick to the base wall overnight. After confirming that the cells adhere well, the medium was changed to a fresh medium containing 10 ppm of each test substance.
시험물질은 하기 표 1에 기재된 바와 같이 사용하였다.Test substances were used as described in Table 1 below.
대조구로는 시험시료의 사용없이 DMSO만 들어 있는 배지를 사용하였다.As a control, a medium containing only DMSO was used without using a test sample.
비교를 위하여, 상기 감초 추출물, 홍삼추출물, 자작나무추출물 및 파파인 효소를 단독으로 사용하는 경우와, 서로 혼합하여 사용하는 경우에 대한 모든 경우의 수를 조합하여 시험하였다.For comparison, the licorice extract, red ginseng extract, birch extract and papain enzyme were tested in combination with the numbers of all cases for use alone and in the case of mixing with each other.
이런 식으로 2일에 한번씩 시료가 들어 있는 새배지로 갈아주면서 세포가 플라스크에 꽉 찰 때까지 배양하였다. 그리고 나서, 배양액을 제거하고 PBS로 세척한 후 1N 수산화나트륨으로 녹여 500nm에서 흡광도를 측정한 후, 하기 식에 따라 대조군에 대한 시료들의 멜라닌 생성 억제율을 계산하여 그 결과를 표 1에 나타내었다.In this way, every two days, the cells were transferred to a new medium containing the sample, and the cells were incubated until the flask was filled. Then, the culture solution was removed, washed with PBS, dissolved with 1N sodium hydroxide, and measured for absorbance at 500 nm. The results of calculating the melanin inhibition rate of the samples for the control group were shown in Table 1 according to the following equation.
(화이트에너지 콤플렉스 1)Example 1
(White Energy Complex 1)
(화이트에너지 콤플렉스 2)Example 2
(White Energy Complex 2)
상기 표 1의 결과로부터 화이트 에너지 콤플렉스를 구성하는 파파인, 홍삼추출물, 자작나무추출물 그 자체의 멜라닌 생성 저해율은 낮았나, 감초와 1가지씩, 2가지씩 조합 사용할 경우 미백효과가 상승되었고, 감초와 상기 3가지 성분을 모두 함께 병행하여 사용하였을 때 미백효과가 더 높아지는 것을 확인할 수 있었다.
From the results of Table 1, the melanin production inhibition rate of papain, red ginseng extract, and birch extract itself constituting the white energy complex was low, but the combination of licorice and one by one, the whitening effect was increased, licorice and the above 3 It was confirmed that the whitening effect is higher when using all the components together in parallel.
<시험예 2> 인체 피부에 대한 미백 효과 시험Test Example 2 Whitening Effect Test on Human Skin
건강한 10명의 남자를 대상으로 피검자의 윗팔뚝 부위에 직경 1.5cm의 구멍 6개가 뚫린 불투명 테이프를 부착한 뒤, 각 피검자의 최소 홍반량(Minimal Erythema Dose)의 1.5∼2배 정도의 자외선(UVB)을 조사하여 피부의 흑화를 유도하고, 시험물질들을 도포한 다음, 두 달 후에 크로마미터를 이용하여 피부의 명암을 측정하였다. After attaching an opaque tape with 6 holes of 1.5cm diameter to the upper forearm of the subject, 10 to 1.5 times as much ultraviolet light (UVB) as the minimum erythema dose (Minimal Erythema Dose) of each subject was examined. Was irradiated to induce blackening of the skin, the test materials were applied, and after 2 months, the contrast of the skin was measured using a chromameter.
각 시험물질들은 하기 표 2에 따른 제형예 및 비교제형예에 따른 제형을 만들어 하루에 2회씩(아침, 저녁) 매일 도포 하였다.
Each test substance was prepared according to the formulation example and comparative formulation according to the following Table 2 and applied twice daily (morning, evening) daily.
<제형예 1, 2 및 비교제형예 1∼4 > 로션 제형<Formulation Examples 1 and 2 and Comparative Formulation Examples 1 to 4> Lotion Formulations
하기의 제형들은 O/W 로션제형으로, 함량단위는 중량%이다. 점도는 제조후 30℃ 항온조에 넣은 후 익일후 측정한 값으로서 점도가 7000∼11000cp이며, pH(10% 수용액기준)는 6.5∼7.5인 제형이다.
The following formulations are in O / W lotion formulations and are in weight percent. Viscosity is the value measured after the day after putting into 30 degreeC thermostat after manufacture, viscosity is 7000-11000cp, pH (10% aqueous solution standard) is 6.5-7.5 formulation.
제조방법Manufacturing method
(1) 유상성분1을 가열(70∼75℃)하여 균일하게 혼합하였다.(1) The oily component 1 was heated (70 to 75 ° C) and mixed uniformly.
(2) 수상성분 1을 가열(70∼75℃)하여 균일하게 용해 및 혼합하였다.(2) The aqueous phase component 1 was heated (70 to 75 ° C) to dissolve and mix uniformly.
(3) 상기 (2)에 상기 (1)을 교반하에 온도(70∼75℃)를 유지한 상태에서 투입하여 에멀젼을 만들고 유상성분 2,수상성분 2를 연속적으로 투입한 후 28∼30℃까지 냉각하였다.
(3) To (2), while stirring (1) above while keeping the temperature (70 to 75 ℃) to make an emulsion, and continuously add the oil component 2, water component 2 to 28 ~ 30 ℃ Cooled.
(화이트에너지 콤플렉스 1)Example 1
(White Energy Complex 1)
(화이트에너지 콤플렉스 2)Example 2
(White Energy Complex 2)
효과의 판정은 피부의 명암을 나타내는 "L"값을 구하여 결정하였다(태우지 않은 한국인피부색은 일반적으로 50∼70의 값을 나타냄). 시험물질을 도포하여 효과가 있는 경우는 L값이 점차 증가하게 되며, 시험물질들 사이의 비교는 ΔL 값(최종 L값 - 시험물질 도포전의 값)으로 표현하였다. ΔL값이 클수록 미백효과가 큰 것이다. 실험 결과에 따른 ΔL값을 표 3에 정리하였다.The determination of the effect was determined by obtaining a "L" value representing the contrast of the skin (unburned Korean skin color generally shows a value of 50 to 70). When the test substance is applied, the L value is gradually increased, and the comparison between the test substances is expressed as ΔL value (final L value-value before application of the test substance). The larger the ΔL value, the greater the whitening effect. The ΔL values according to the experimental results are summarized in Table 3.
표 3의 실험 결과를 보면 감초 단독으로 사용한 비교예 1 및 파파인, 자작나무추출물, 홍삼추출물을 감초와 각각 사용한 비교 제형예 2, 3, 4에서보다 상기 3가지를 함께 사용한 제혀예 1 및 2에서 ΔL의 값이 더 높은 것으로 나타났으며 이는 미백효과가 상대적으로 더 큰 것으로 나타났다. Experimental results of Table 3 shows that in Comparative Example 1 using paprika alone, papain, birch extract, and red ginseng extract using Licorice and Licorice extract, respectively. The value of ΔL was higher, indicating that the whitening effect is relatively greater.
그리고 상기 화이트 에너지 콤플렉스의 양이 많을수록 상대적으로 더 큰 미백효과가 있음을 확인할 수 있었다.And it was confirmed that the greater the amount of the white energy complex has a relatively greater whitening effect.
이상에서 설명한 바와 같이, 본 발명의 미백용 조성물인 화이트 에너지 콤플렉스를 이용하여 수중유형 에멀젼의 화장료 조성물을 제조하여 미백 증진 효과를 확인한 결과 미백효과가 증진됨을 확인할 수 있었다.
As described above, using the white energy complex of the whitening composition of the present invention to prepare a cosmetic composition of the oil-in-water emulsion, confirming the whitening enhancement effect was confirmed that the whitening effect is enhanced.
Claims (4)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040002910A KR101072133B1 (en) | 2004-01-15 | 2004-01-15 | Skin whitening composition having synergic whitening effect |
PCT/KR2005/000146 WO2005067885A1 (en) | 2004-01-15 | 2005-01-14 | Skin whitening composition having synergic whitening effect |
JP2006549140A JP4660487B2 (en) | 2004-01-15 | 2005-01-14 | Cosmetic composition for increasing skin whitening effect |
CNB2005800023623A CN100459970C (en) | 2004-01-15 | 2005-01-14 | Skin whitening composition having synergic whitening effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040002910A KR101072133B1 (en) | 2004-01-15 | 2004-01-15 | Skin whitening composition having synergic whitening effect |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050075115A KR20050075115A (en) | 2005-07-20 |
KR101072133B1 true KR101072133B1 (en) | 2011-10-10 |
Family
ID=34793252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040002910A KR101072133B1 (en) | 2004-01-15 | 2004-01-15 | Skin whitening composition having synergic whitening effect |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP4660487B2 (en) |
KR (1) | KR101072133B1 (en) |
CN (1) | CN100459970C (en) |
WO (1) | WO2005067885A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101682123B1 (en) | 2015-10-12 | 2016-12-02 | (주)솔티패밀리그룹 | Cosmetic composition comprising birch sap and herbal extracts for skin whitening and improvement of skin barrier function, and cosmetic comprising the same |
KR20170058562A (en) | 2015-11-19 | 2017-05-29 | 대봉엘에스 주식회사 | METHOD FOR PREPARING AN LICORICE EXTRACT OF Nrf-2 ACTIVATOR, AND COSMETIC COMPOSITION COMPRISING THE SAME |
KR20200140562A (en) | 2019-06-07 | 2020-12-16 | 안준민 | Cosmetic composition for skin whitening comprising black-ginseng fermentation extract |
KR20220092199A (en) | 2020-12-24 | 2022-07-01 | 제너럴바이오(주) | Composition comprising fermented Glycyrrhiza uralensis extract for inhibitory effects on melanogenesis of B16F10 cells |
KR20220095853A (en) | 2020-12-30 | 2022-07-07 | 제너럴바이오(주) | a composition comprising Fomitella fraxinea mycelium, Ganoderma applanatum mycelium and Glycyrrhizae uralensis extract for inhibitory effects on melanogenesis of B16F10 cells |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100841276B1 (en) * | 2006-12-18 | 2008-06-25 | 한국식품연구원 | Skin Whitening Composition Containing Ethyl Acetate Fraction of White Ginseng with High Whitening Activity |
US9364424B2 (en) | 2007-11-19 | 2016-06-14 | Stiefel Laboratories, Inc. | Topical cosmetic skin lightening compositions and methods of use thereof |
BRPI0722043A2 (en) * | 2007-11-19 | 2016-10-18 | Stiefel Laboratories | topical cosmetic skin whitening compositions and methods of using them. |
US9241893B2 (en) | 2007-11-19 | 2016-01-26 | Stiefel Laboratories, Inc. | Topical cosmetic skin lightening compositions and methods of use thereof |
JP5414236B2 (en) * | 2008-10-10 | 2014-02-12 | 丸善製薬株式会社 | Anti-inflammatory agent |
US8440237B2 (en) | 2009-04-27 | 2013-05-14 | Mary Kay Inc. | Botanical anti-acne formulations |
KR101382114B1 (en) | 2009-11-30 | 2014-04-08 | (주)아모레퍼시픽 | Skin external composition containing red ginseng polysaccharide extract |
CN107961192B (en) | 2011-12-19 | 2021-09-24 | 玫琳凯有限公司 | Application of composition containing red bean extract |
CN104056036A (en) * | 2013-03-21 | 2014-09-24 | 刘宝英 | Health care composition capable of whitening and removing freckle |
US9849077B2 (en) | 2014-03-10 | 2017-12-26 | Mary Kay Inc. | Skin lightening compositions |
JP6583704B2 (en) * | 2014-09-25 | 2019-10-02 | ポーラ化成工業株式会社 | Screening method for pigmentation improvers |
KR101707107B1 (en) | 2015-05-20 | 2017-02-16 | 주식회사 콧데 | Composition for multi-functional activation comprising Liquiritigenin |
KR102598793B1 (en) | 2015-09-23 | 2023-11-07 | (주)아모레퍼시픽 | Composition comprising ginseng derived exosome like vesicles for skin whitening |
WO2017052242A1 (en) * | 2015-09-23 | 2017-03-30 | (주)아모레퍼시픽 | Lightening composition comprising ginseng-derived exosome-like vesicles |
CN112386548A (en) * | 2020-11-13 | 2021-02-23 | 深圳市薇美经典科技发展有限公司 | Freckle-removing skin-brightening preparation and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003246724A (en) | 2002-02-25 | 2003-09-02 | Kanebo Ltd | Whitening cosmetic |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1230926A4 (en) * | 1999-10-14 | 2006-03-15 | Nisshin Oillio Ltd | Skin-care agents, skin antiaging agents, whitening agents and external skin preparations |
CA2404012A1 (en) * | 2000-03-31 | 2001-10-04 | The Nisshin Oil Mills, Ltd. | External agent for the skin and whitening agent |
JP2001335498A (en) * | 2000-05-26 | 2001-12-04 | Nippon Flour Mills Co Ltd | Bleaching composition and food and cosmetic comprising the same |
KR100357416B1 (en) * | 2000-08-22 | 2002-10-19 | 오세군 | Compositions of whitening cosmetics containing special herbal extracts |
KR100493845B1 (en) * | 2001-07-04 | 2005-06-08 | 한국화장품주식회사 | Whitening cosmetic composition containing the extract of mountain ginseng adventitious roots |
JP2003081751A (en) * | 2001-09-07 | 2003-03-19 | Sanburen:Kk | Papaya powder-formulated water-containing cosmetic |
-
2004
- 2004-01-15 KR KR1020040002910A patent/KR101072133B1/en active IP Right Grant
-
2005
- 2005-01-14 CN CNB2005800023623A patent/CN100459970C/en not_active Expired - Fee Related
- 2005-01-14 WO PCT/KR2005/000146 patent/WO2005067885A1/en active Application Filing
- 2005-01-14 JP JP2006549140A patent/JP4660487B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003246724A (en) | 2002-02-25 | 2003-09-02 | Kanebo Ltd | Whitening cosmetic |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101682123B1 (en) | 2015-10-12 | 2016-12-02 | (주)솔티패밀리그룹 | Cosmetic composition comprising birch sap and herbal extracts for skin whitening and improvement of skin barrier function, and cosmetic comprising the same |
KR20170058562A (en) | 2015-11-19 | 2017-05-29 | 대봉엘에스 주식회사 | METHOD FOR PREPARING AN LICORICE EXTRACT OF Nrf-2 ACTIVATOR, AND COSMETIC COMPOSITION COMPRISING THE SAME |
KR20200140562A (en) | 2019-06-07 | 2020-12-16 | 안준민 | Cosmetic composition for skin whitening comprising black-ginseng fermentation extract |
KR20220092199A (en) | 2020-12-24 | 2022-07-01 | 제너럴바이오(주) | Composition comprising fermented Glycyrrhiza uralensis extract for inhibitory effects on melanogenesis of B16F10 cells |
KR20220095853A (en) | 2020-12-30 | 2022-07-07 | 제너럴바이오(주) | a composition comprising Fomitella fraxinea mycelium, Ganoderma applanatum mycelium and Glycyrrhizae uralensis extract for inhibitory effects on melanogenesis of B16F10 cells |
Also Published As
Publication number | Publication date |
---|---|
JP2007517866A (en) | 2007-07-05 |
CN1909885A (en) | 2007-02-07 |
JP4660487B2 (en) | 2011-03-30 |
KR20050075115A (en) | 2005-07-20 |
WO2005067885A1 (en) | 2005-07-28 |
CN100459970C (en) | 2009-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101072133B1 (en) | Skin whitening composition having synergic whitening effect | |
KR101823036B1 (en) | Inhibitor of melanin synthesis and the cosmetic composition containing the same | |
JP3638832B2 (en) | Cosmetic and / or dermatological composition comprising at least one mulberry extract, at least one seaweed extract and at least one salicylic acid derivative | |
KR100760875B1 (en) | Compositions for whitening skin by inhibition of melanin synthesis | |
EP0970693B1 (en) | Biologically active labdane or labdene derivatives from Cistus | |
KR100710657B1 (en) | Whitening cosmetic composition containing dihydroquercetin | |
JPWO2016121962A1 (en) | Melanin production inhibitor | |
KR20090091505A (en) | Composition for skin whitening containing oxygen dissolving water | |
JPH0987164A (en) | Skin preparation for external use | |
TW201622695A (en) | External dermatological agent for anti-ageing | |
JP6513469B2 (en) | The external preparation for skin and the internal preparation containing the extract of the Chinese cabbage which is grown by irradiating the light which has a specific wavelength range. | |
JPH01207225A (en) | Cosmetic for hair | |
KR101317433B1 (en) | The cosmetic composition for skin whitening comprising the mixture of extract of Hovenia dulcia, Platycodon grandiflorum, wheat bud and sage | |
KR101151007B1 (en) | Cosmetic composition comprising Rucinol and Niacinamide for Skin-Whitening | |
KR20090050856A (en) | Skin whitening cosmetic composition containing fraction extract of cimicifuga heracleifolia extracts, manufacturing method thereof | |
KR100795515B1 (en) | Composition for skin whitening comprising artemisinine | |
KR20160020253A (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising atractylenolide I | |
KR20160020242A (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising parthenolide | |
KR20160020223A (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising Shanzhiside methylester or a pharmaceutically acceptable salt thereof | |
JPH0987135A (en) | Dermal preparation for external use | |
KR102430512B1 (en) | Reelin/vegf-c production/activation promoter and skin external composition using the same | |
JP2011511063A (en) | Skin whitening agent containing platicodine-D | |
KR100821482B1 (en) | External skin application composition for skin whitening | |
KR20070079390A (en) | Cosmetic composition for skin whitening | |
KR20160020250A (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising Wogonoside or a pharmaceutically acceptable salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150914 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170928 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181001 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190926 Year of fee payment: 9 |